Web68 Ga-PSMA PET/CT for response assessment and outcome prediction in metastatic prostate cancer patients treated with taxane-based chemotherapy 68 Ga-PSMA PET/CT for response assessment and outcome prediction in metastatic prostate cancer patients treated with taxane-based chemotherapy WebNov 29, 2024 · In conclusion, this phase 2 trial demonstrates 177 Lu-PSMA-617 to be non-inferior to docetaxel for achieving PSA response in chemotherapy-naïve mCRPC with an acceptable safety profile. However, further large-scale trials are required to validate our observations and determine the specific sequence of treatment options for these patients.
Kenali PSMA sebagai Obat Baru untuk Kanker Prostat Stadium …
WebApr 14, 2024 · Chemotherapy for mCRPC is predominantly taxane-based regimens. Since 2004, DOC obtained FDA approval as the first-line treatment for mCRPC. as it extended median overall survival (OS) by 2 to 3 months for detectable mCRPC. ... Prostate-specific membrane antigen (PSMA) is a type II transmembrane glycoprotein that is increased in … WebPSMA therapy aims to improve your symptoms and reduce the size of your tumors. It can also slow their growth and prevent bone fractures. Afterward, some people experience a period of remission, but it doesn’t cure the cancer. It’s used when cancer has metastasized and other treatments have failed. Who it’s for boss trailer nahu
Cancers Free Full-Text PSMA PET Imaging and Therapy in …
WebNov 29, 2024 · Prior chemotherapy has been shown to be a worse predictor of response and survival outcomes with 177 Lu-PSMA-RLT [22–24]. In a retrospective study, Barber et al. … WebFeb 3, 2024 · At present, the main treatment methods for prostate cancer include radical surgical resection, radiotherapy, chemotherapy, local radiotherapy, androgen deprivation therapy, targeted therapy, and immunotherapy. As the condition of the patient progresses, the efficacy of these therapies will gradually decrease or even be completely ineffective ( … WebMar 23, 2024 · Pluvicto TM (lutetium Lu 177 vipivotide tetraxetan) is indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have already been treated with other anticancer treatments (androgen receptor pathway inhibition (ARPI) and taxane … boss tracksuit men